Inhibiting JAK1, not NF-κB, reverses the effect of pro-inflammatory cytokines on engineered human ligament function

Matrix Biol. 2024 Jan:125:100-112. doi: 10.1016/j.matbio.2023.12.007. Epub 2023 Dec 25.

Abstract

The role of inflammation in chronic tendon/ligament injury is hotly debated. There is less debate about inflammation following acute injury. To better understand the effect of acute inflammation, in this study we developed a multi-cytokine model of inflammatory tendinitis. The combined treatment with TNF-α, IL-1β, and IL-6, at dosages well below what are routinely used in vitro, decreased the mechanical properties and collagen content of engineered human ligaments. Treatment with this cytokine mixture resulted in an increase in phospho-NF-κB and MMP-1, did not affect procollagen production, and decreased STAT3 phosphorylation relative to controls. Using this more physiologically relevant model of acute inflammation, we inhibited NF-κB or JAK1 signaling in an attempt to reverse the negative effects of the cytokine mixture. Surprisingly, NF-κB inhibition led to an even greater decrease in mechanical function and collagen content. By contrast, inhibiting JAK1 led to an increase in mechanical properties, collagen content and thermal stability concomitant with a decrease in MMP-1. Our results suggest that inhibition of JAK1, not NF-κB, reverses the negative effects of pro-inflammatory cytokines on collagen content and mechanics in engineered human ligaments.

Keywords: Collagen; Exercise; Inflammation; Mechanics; NF-κB; STAT3.

MeSH terms

  • Collagen
  • Cytokines*
  • Humans
  • Inflammation
  • Janus Kinase 1 / genetics
  • Ligaments
  • Matrix Metalloproteinase 1 / genetics
  • NF-kappa B* / genetics
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • NF-kappa B
  • Cytokines
  • Matrix Metalloproteinase 1
  • Tumor Necrosis Factor-alpha
  • Collagen
  • JAK1 protein, human
  • Janus Kinase 1